R&D Partner Content The 3rd Next-Generation Conjugates Summit is back! Driving Innovation and Pioneering Novel Payload & Format Conjugate Design
R&D Partner Content 6th Treg Directed Therapies Summit Get ready for the much-anticipated return of the 6th Treg-Directed Therapies Summit! This year promises an enhanced experience wi
R&D Partner Content 4th Gene Therapy for Muscular Disorders 2024 4th Gene Therapy for Muscular Disorders Summit (April 16-18, Boston)
R&D Partner Content 5th RNA Editing Summit 2024 Pioneering RNA Editing Drugs Towards Clinical Realities
R&D Partner Content Obesity & Weight Loss Drug Development Summit Next Generation of GLP & Weight Loss Therapies
R&D Partner Content 3rd World ADC Asia Optimising Physiochemical, Potency & Impurity Analytical Methods to Ensure Regulatory Compliance
News ASH: Regeneron makes frontline case for Lynozyfic in myeloma Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
